Trial Profile
A phase II study of AZD2171 [cediranib] in subjects with recurrent small volume ovarian, primary peritoneal serous or fallopian tube cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 24 Feb 2012 Planned End Date changed from 1 May 2006 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.